Hannah Kiely-Collins

Crazy new pre-print from TSRI: fix whole mice, clear them transparent, click on fluorophores, & use light sheet microscopy to visualize where drugs bind throughout the body. Find ibrutinib-yne in low BTK heart & blood vessels, correlates with cardiac side effects.

www.biorxiv.org/content/10.1...

high quality conference stash 👌🧦 #ABPP2025 @li-corenv.bsky.social @selvita

CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery - Nature Microbiology A CRISPR-based oligo recombineering (CORe) approach functionally prioritizes electrophile-sensitive cysteines in Toxoplasma gondii and promotes anti-parasitic drug discovery.

To close the first session, Matt Child will discuss advances in high-throughout chemoproteogenomics 🧫 His group have previously used a chemoproteomic approach combined with CRISPR to identify reactive cysteines in Toxoplasma gondii www.nature.com/articles/s41...

Enhanced mapping of small-molecule binding sites in cells - Nature Chemical Biology A chemoproteomic workflow was developed to determine the interaction sites of photoaffinity probes in cells, enabling the identification of diverse binding pockets and providing evidence of their trac...

Excited for @chrisgparker.bsky.social ‘s talk about Photoaffinity-based Chemical Proteomics! ⚡️
His group’s work to simplify the identification of the labelling site of diazirine-based probes using predictive models is very cool, amongst other recent PAL developments

www.nature.com/articles/s41...

Profiling the proteome-wide selectivity of diverse electrophiles Targeted covalent inhibitors are powerful entities in drug discovery, but their application has so far mainly been limited to addressing cysteine residues. The development of cysteine-directed covalen...

Next up we’ll have a talk from @stephanhacker2.bsky.social about identifying electrophiles to target amino acids beyond cysteine, including the first probes to globally monitor tryptophans, histidines and arginines ✨

chemrxiv.org/engage/chemr...

A Small-Molecule Inhibitor of Gut Bacterial Urease Protects the Host from Liver Injury Hyperammonemia is characterized by the accumulation of ammonia within the bloodstream upon liver injury. Left untreated, hyperammonemia contributes to conditions such as hepatic encephalopathy that ha...

First keynote speaker is Emily Balskus, whose lab focus on developing chemical modulators of the human microbiome, such as small molecule urease inhibitors to prevent liver injury.

pubs.acs.org/doi/10.1021/...

The sun is shining in London for the first day of #ABPP2025 ! Really excited to welcome everyone to the Crick later with an incredible lineup for the first session @abpp2025.bsky.social

Discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq Targeted protein degradation (TPD) is an emerging therapeutic modality in which small molecules are used to recruit targets to the natural protein degradation machinery of the cell. Molecular glue deg...

🚨 Rational discovery of VHL molecular glues. New Preprint from @amgen.bsky.social Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/8 www.biorxiv.org/content/10.1...

A black-and-white photo shows a woman in a patterned dress with a lace collar and pearl necklace, sitting in a chair. The background features shelves with bottles and a wire basket, suggesting an early 20th-century setting, possibly a pharmacy or study.

On this day in 1879, Maud Menten was born in Port Lambton, Ontario.
In her work as a medical researcher, she became a leading expert in histochemistry and enzyme kinetics while fighting against sexism in her field.
Let's learn more about her life!

🧵1/10

This excellent commentary is a must-read for cancer biologists (and all biologists, really).
Probing cancer with small-molecule tools—Progress and challenges: Cancer Cell www.cell.com/cancer-cell/...

A Bifunctional Degrader Reads Out in Phase 3

The first bifunctional protein degrader to deliver Phase III data! It seems to work, but people were definitely expecting more:

An auditorium full of people looking at a stage with a presenter and a slide saying "Enabling Discovery: Chemistry at the Crick" along with the event sponsors

This week we hosted the inaugural Chemistry at the @crick.ac.uk symposium. Nearly 200 attendees enjoyed great talks from a range of group leaders across chemistry, biology, and translation. Huge thanks to our sponsors Cresset, IDT, Buchi, Merck, Dotmatics, WuXi, MedChem Express, and Enamine

Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic Halda Therapeutics has started a clinical trial of its first-in-modality RIPTAC drug HLD-0915 in prostate cancer, to see if bifunctional drugs can provide tissue-specific activity.

www.nature.com/articles/d41... #RIPTACs

Molecular glue unexpectedly mimics the effect of cancer mutations Protein structures could guide the design of molecular glue degraders.

Happy to share a @nature.com News and Views on the amazing discoveries by @brianliau.bsky.social & Ning Zheng labs on how a molecular glue unexpectedly mimics the effect of cancer mutations. Such cool science and with implications to drug discovery. Check it out. www.nature.com/articles/d41...

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.

Check out our recent efforts in chemrxiv to expand the chemical tractability of the proteome through NP-inspired photoaffinity probes

chemrxiv.org/engage/chemr...